Bakare Ajibola B, Lesnefsky Edward J, Iyer Shilpa
Department of Biological Sciences, J. William Fulbright College of Arts and Sciences, University of Arkansas, Fayetteville, AR, United States.
Division of Cardiology, Pauley Heart Center, Department of Internal Medicine, School of Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Front Physiol. 2021 Aug 11;12:693734. doi: 10.3389/fphys.2021.693734. eCollection 2021.
Leigh syndrome is a rare, complex, and incurable early onset (typically infant or early childhood) mitochondrial disorder with both phenotypic and genetic heterogeneity. The heterogeneous nature of this disorder, based in part on the complexity of mitochondrial genetics, and the significant interactions between the nuclear and mitochondrial genomes has made it particularly challenging to research and develop therapies. This review article discusses some of the advances that have been made in the field to date. While the prognosis is poor with no current substantial treatment options, multiple studies are underway to understand the etiology, pathogenesis, and pathophysiology of Leigh syndrome. With advances in available research tools leading to a better understanding of the mitochondria in health and disease, there is hope for novel treatment options in the future.
Leigh综合征是一种罕见、复杂且无法治愈的早发性(通常为婴儿期或幼儿期)线粒体疾病,具有表型和遗传异质性。这种疾病的异质性部分基于线粒体遗传学的复杂性,以及核基因组与线粒体基因组之间的显著相互作用,这使得研究和开发治疗方法极具挑战性。这篇综述文章讨论了该领域迄今为止取得的一些进展。虽然目前预后很差且没有实质性的治疗选择,但多项研究正在进行中,以了解Leigh综合征的病因、发病机制和病理生理学。随着现有研究工具的进步,人们对健康和疾病状态下的线粒体有了更好的理解,未来有望出现新的治疗选择。